Greenleaf Trust Sells 2,671 Shares of DexCom, Inc. (NASDAQ:DXCM)

Greenleaf Trust trimmed its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 18.4% during the third quarter, HoldingsChannel reports. The fund owned 11,840 shares of the medical device company’s stock after selling 2,671 shares during the quarter. Greenleaf Trust’s holdings in DexCom were worth $794,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in DXCM. Vanguard Group Inc. lifted its position in shares of DexCom by 0.3% in the 1st quarter. Vanguard Group Inc. now owns 44,603,745 shares of the medical device company’s stock worth $6,186,539,000 after purchasing an additional 136,282 shares during the period. Blair William & Co. IL lifted its position in shares of DexCom by 1.4% in the 1st quarter. Blair William & Co. IL now owns 4,532,687 shares of the medical device company’s stock worth $628,684,000 after purchasing an additional 64,683 shares during the period. Legal & General Group Plc lifted its position in shares of DexCom by 1.7% in the 2nd quarter. Legal & General Group Plc now owns 2,993,049 shares of the medical device company’s stock worth $339,352,000 after purchasing an additional 49,076 shares during the period. Massachusetts Financial Services Co. MA lifted its position in shares of DexCom by 16.9% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company’s stock worth $276,538,000 after purchasing an additional 353,019 shares during the period. Finally, 1832 Asset Management L.P. lifted its position in shares of DexCom by 1.1% in the 1st quarter. 1832 Asset Management L.P. now owns 1,823,400 shares of the medical device company’s stock worth $252,906,000 after purchasing an additional 20,400 shares during the period. 97.75% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the transaction, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at $5,217,436.65. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the transaction, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at $5,217,436.65. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the transaction, the chief operating officer now directly owns 264,915 shares in the company, valued at $18,318,872.25. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,824 shares of company stock worth $126,390. Insiders own 0.30% of the company’s stock.

DexCom Stock Performance

DXCM opened at $74.85 on Friday. The company has a current ratio of 2.82, a quick ratio of 2.48 and a debt-to-equity ratio of 1.00. The company’s fifty day moving average price is $70.13 and its two-hundred day moving average price is $98.71. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The company has a market cap of $29.77 billion, a price-to-earnings ratio of 48.29, a PEG ratio of 2.16 and a beta of 1.18.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.04. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter in the prior year, the company posted $0.34 earnings per share. The business’s revenue was up 15.3% on a year-over-year basis. On average, analysts expect that DexCom, Inc. will post 1.69 EPS for the current fiscal year.

Analyst Ratings Changes

DXCM has been the topic of a number of recent analyst reports. Wells Fargo & Company dropped their price target on shares of DexCom from $145.00 to $80.00 and set an “overweight” rating on the stock in a research report on Friday, July 26th. BTIG Research dropped their price target on shares of DexCom from $156.00 to $120.00 and set a “buy” rating on the stock in a research report on Friday, July 26th. Baird R W downgraded shares of DexCom from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 26th. Stifel Nicolaus boosted their target price on shares of DexCom from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, August 23rd. Finally, Royal Bank of Canada dropped their target price on shares of DexCom from $130.00 to $120.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Seven analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, DexCom presently has an average rating of “Moderate Buy” and a consensus price target of $110.73.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.